Vanguard Group Inc Dyne Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
205Shares Held
105MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$239 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$234 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$220 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$190 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$180 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.54B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...